Lyme disease

New England Journal of Medicine

Volumn 345, Issue 2, 2001, Pages 115-125

  Steere, Allen C ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME AXETIL; DOXYCYCLINE; ERYTHROMYCIN; LYME DISEASE VACCINE; PENICILLIN G;

ARTHRITIS; ARTHROPATHY; ATRIOVENTRICULAR BLOCK; BORRELIA BURGDORFERI; CLINICAL FEATURE; FACIAL NERVE PARALYSIS; HEART DISEASE; HUMAN; INCIDENCE; IXODES; LYME DISEASE; NEUROLOGIC DISEASE; NONHUMAN; PATHOGENESIS; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION; UNITED STATES; VACCINATION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BORRELIA BURGDORFERI GROUP; DISEASE VECTORS; DOXYCYCLINE; ERYTHEMA CHRONICUM MIGRANS; HUMANS; IXODES; LYME DISEASE; LYME DISEASE VACCINES;

EID: 0035849985     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200107123450207     Document Type: Review

References (100)

1. Lyme arthritis: An epidemic of oligoarticular arthritis in children and adults in three Connecticut communities
2. Lyme disease - A tick-borne spirochetosis?
3. The spirochetal etiology of Lyme disease
4. Lyme disease
5. Surveillance for Lyme disease - United States, 1992-1998
6. Epidemiology of Lyme borreliosis
7. Lyme borreliosis: Relation of its causative agent to its vectors and hosts in North America and Europe
8. The emergence of Lyme disease and human babesiosis in a changing environment
9. Lyme disease in California: A novel enzootic transmission cycle of Borrelia burgdorferi
10. Epidemiologic and diagnostic studies of patients with suspected early Lyme disease, Missouri, 1990-1993
11. Biology of Borrelia species
12. Genomic sequence of a Lyme disease spirochete, Borrelia burgdorferi
13. Arthropod- and host-specific gene expression by Borrelia burgdorferi
14. Genetic variation of the Borrelia burgdorferi gene vlsE involves cassette-specific, segmental gene conversion
15. Delineation of Borrelia burgdorferi sensu stricto, Borrelia garinii sp. nov., and group VS461 associated with Lyme borreliosis
16. Comparison of culture-confirmed erythema migrans caused by Borrelia burgdorferi sensu stricto in New York State and by Borrelia afzelii in Slovenia
17. Comparison of the yields of blood cultures using serum or plasma from patients with early Lyme disease
18. Four clones of Borrelia burgdorferi sensu stricto cause invasive infection in humans
19. Plasminogen is required for efficient dissemination of B. burgdorferi in ticks and for enhancement of spirochetemia in mice
20. 3 mediates binding of the Lyme disease agent Borrelia burgdorferi to human platelets
21. 1 mediate attachment of Lyme disease spirochetes to human cells
22. Decorin-binding adhesins from Borrelia burgdorferi
23. Identification of a 47 kDa fibronectin-binding protein expressed by Borrelia burgdorferi isolate B31
24. Resistance to Lyme disease in decorin deficient mice
25. Identification of quantitative trait loci governing arthritis severity and humoral responses in the murine model of Lyme disease
26. Exacerbation of Lyme arthritis in beige mice
27. Inflammatory signaling by Borrelia burgdorferi lipoproteins is mediated by toll-like receptor 2
28. T-helper-cell cytokines in the early evolution of murine Lyme arthritis
29. Differential expression of cytokine mRNA in skin specimens from patients with erythema migrans or acrodermatitis chronica atrophicans
30. T cell proliferation induced by Borrelia burgdorferi in patients with Lyme borreliosis: Autologous serum required for optimum stimulation
31. The immunoglobin (IgG) antibody response to OspA and OspB correlates with severe and prolonged Lyme arthritis and the IgG response to P35 correlates with mild and brief arthritis
32. Successful cultivation of spirochetes from skin lesions of patients with erythema chronicum migrans Afzelius and acrodermatitis chronica atrophicans
33. Modulation of immunity to Borrelia burgdorferi by ultraviolet irradiation: Differential effect on Th1 and Th2 immune responses
34. Stages and syndromes of neuroborreliosis
35. Optic neuropathy in children with Lyme disease
36. Pathogenesis of Lyme neuroborreliosis in the rhesus monkey: The early disseminated and chronic phases of disease in the peripheral nervous system
37. Localization of Borrelia burgdorferi in the nervous system and other organs in a nonhuman primate model of Lyme disease
38. Chronic neurologic manifestations of Lyme disease
39. Clinical and electrophysiologic findings in chronic neuropathy of Lyme disease
40. Lyme neuroborreliosis: Central nervous system manifestations
41. Successful treatment of Lyme encephalopathy with intravenous ceftriaxone
42. Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease
43. Cytokines in murine Lyme carditis: Th1 cytokine expression follows expression of proinflammatory cytokines in a susceptible mouse strain
44. Protective and arthritis-resolving activity in sera of mice infected with Borrelia burgdorferi
45. Isolation of Borrelia burgdorferi from the myocardium of a patient with longstanding cardiomyopathy
46. Isolation of Borrelia burgdorferi from myocardium
47. A prospective study of the seroprevalence of Borrelia burgdorferi infection in patients with severe heart failure
48. Spirochetal antigens and lymphoid cell surface markers in Lyme synovitis: Comparison with rheumatoid synovium and tonsillar lymphoid tissue
49. Lyme arthritis synovial γδ T cells respond to Borrelia burgdorferi lipoproteins and lipidated hexapeptides
50. Association of antibiotic treatment-resistant Lyme arthritis with T cell responses to dominant epitopes of outer surface protein A of Borrelia burgdorferi
51. T helper 1 response is dominant and localized to the synovial fluid in patients with Lyme arthritis
52. T cell cytokine pattern in the joints of patients with Lyme arthritis and its regulation by cytokines and anticytokines
53. Western blotting in the serodiagnosis of Lyme disease
54. Lyme borreliosis in selected strains and ages of laboratory mice
55. Lyme arthritis resolution with antiserum to a 37-kilodalton Borrelia burgdorferi protein
56. Association of chronic, treatment-resistant Lyme arthritis with rheumatoid arthritis (RA) alleles
57. Treatment of Lyme arthritis
58. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis
59. Lack of Borrelia burgdorferi DNA in synovial samples in patients with antibiotic treatment-resistant Lyme arthritis
60. Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi
61. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis
62. + T cells ex vivo by using MHC class II tetramers
63. Molecular mimicry in Lyme arthritis demonstrated at the single cell level: LFA-1α is a partial agonist for outer surface protein A-reactive T cells
64. Cultivation of Borrelia burgdorferi from erythema migrans lesions and perilesional skin
65. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in cerebrospinal fluid in patients with Lyme neuroborreliosis
66. Intralaboratory reliability of serologic and urine testing for Lyme disease
67. Case definitions for public health surveillance
68. Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease
69. A European multicenter study of immunoblotting in serodiagnosis of Lyme borreliosis
70. Immunoblot interpretation criteria for serodiagnosis of early Lyme disease
71. Evaluation of the intrathecal antibody response to Borrelia burgdorferi as a diagnostic test for Lyme neuroborreliosis
72. Persistence of IgM or IgG antibody responses to Borrelia burgdorferi 10 to 20 years after active Lyme disease
73. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant
74. Prevalence of tick-borne encephalitis and Lyme borreliosis in a defined Swedish population
75. Recombinant chimeric Borrelia proteins for diagnosis of Lyme disease
76. Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of Borrelia burgdorferi vlsE
77. Practice guidelines for the treatment of Lyme disease
78. Test-treatment strategies for patients suspected of having Lyme disease: A cost-effectiveness analysis
79. Recommendations for the use of Lyme disease vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
80. Maternal Lyme disease and congenital malformations: A cord blood serosurvey in endemic and control areas
81. Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis
82. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease
83. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease
84. Failure of treatment with cephalexin for Lyme disease
85. Treatment of late Lyme borreliosis - Randomised comparison of ceftriaxone and penicillin
86. Cefotaxime vs penicillin G for acute neurologic manifestations of Lyme borreliosis: A prospective randomized study
87. Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis
88. Cost effectiveness of oral as compared with intravenous antibiotic therapy for patients with early Lyme disease or Lyme arthritis
89. Lyme disease associated with fibromyalgia
90. Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease
91. Evaluation of study patients with Lyme disease, 10-20-year follow-up
92. Longterm outcomes of persons with Lyme disease
93. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease
94. Biliary complications in the treatment of unsubstantiated Lyme disease
95. Death from inappropriate therapy for Lyme disease
96. A controlled trial of antimicrobial prophylaxis for Lyme disease after deer-tick bites
97. Dynamics of Borrelia burgdorferi transmission by nymphal Ixodes dammini ticks
98. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite
99. Safety and immunogenicity profile of a recombinant outer-surface protein A Lyme disease vaccine: Clinical trial of a 3-dose schedule at 0, 1, and 2 months